Actinomycin D Arrests Cell Cycle of Hepatocellular Carcinoma Cell Lines and Induces p53-Dependent Cell Death: A Study of the Molecular Mechanism Involved in the Protective Effect of IRS-4

Actinomycin D (ActD) is an FDA-approved NCI oncology drug that specifically targets and downregulates stem cell transcription factors, which leads to a depletion of stem cells within the tumor bulk. Recently, our research group demonstrated the importance of IRS-4 in the development of liver cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Guijarro, Luis G., Sanmartin-Salinas, Patricia, Pérez-Cuevas, Eva, Toledo-Lobo, M. Val, Monserrat, Jorge, Zoullas, Sofia, Sáez, Miguel A., Álvarez-Mon, Miguel Angel, Bujan, Julia, Noguerales-Fraguas, Fernando, Arilla-Ferreiro, Eduardo, Álvarez-Mon, Melchor, Ortega, Miguel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472101/
https://www.ncbi.nlm.nih.gov/pubmed/34577545
http://dx.doi.org/10.3390/ph14090845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472101/
https://www.ncbi.nlm.nih.gov/pubmed/34577545
http://dx.doi.org/10.3390/ph14090845

Ejemplares similares